In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Eyeing ‘Sustainable Opportunities’ In Non-US Biosimilars Markets

Executive Summary

As it begins reporting biosimilars sales after embarking on the journey a decade ago, Amgen says it will target sizeable European countries possessing more “balanced dynamics,” such as France and Germany, for its biosimilar franchise. The California-based biotech also remains upbeat about the potential to make serious inroads in the US biosimilars market.

You may also be interested in...

Biosimilars Begin To 'Pay Off' For Biocon

Biocon rang in a strong Q3, buoyed by the momentum in its biologics business. The firm appears undeterred by suggestions that the US biosimilars market may be less attractive than initially anticipated.

Products Roundup - 19 December 2018: European Commission Approves Mylan/Biocon’s Ogivri Biosimilar, Amgen Files Infliximab With The FDA And Hikma Debuts Dalfampridine

The latest generic, biosimilar and value-added drug development news and highlights from across the globe.

Amgen handed CRL on trastuzumab in US

Amgen received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for its Kanjinti (trastuzumab) biosimilar following a recent target action date, the company has disclosed to Generics bulletin. Responding to enquiries, an Amgen spokesperson said the response letter – informing the firm that its biologics license application (BLA) is not yet ready for approval – was not expected to “impact our US launch plan”. The US-based firm, however, did not expand on its launch strategy.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts